CLINICAL TRIAL: OGF & GEMCITABINE: NOVEL TREATMENT FOR PANCREATIC CANCER

临床试验：OGF

• 批准号: 7951267
• 负责人: Jill P Smith
• 金额: $ 0.97万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951267
• 关键词: Biological Response Modifier Therapy; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Disease Progression; Funding; Grant; Institution; Malignant neoplasm of pancreas; Patients; Protocols documentation; Research; Research Personnel; Resources; Safety; Source; Time; Toxic effect; United States National Institutes of Health; chemotherapy; gemcitabine; novel; safety testing

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary objective of this protocol is to evaluate the safety and toxicity of the combination of OGF biotherapy and gemcitabine chemotherapy. The purpose of this objective is to test the safety and toxicity of the combination treatments OGF and gemcitabine. Additionally , the efficacy of OGF biotherapy and gemcitabine chemotherapy on time to progression of disease in patients with advanced pancreatic cancer compared with those treated with standard chemotherapy (gemcitabine) alone will be evaluated.

这个子项目是众多研究子项目之一